Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • (NewsVoir); Aggressively moving towards its expansion plans, 1mg.com - India’s leading m-health platform that has also been operating the largest e-Pharmacy marketplace in the country, announced today that it has decided to expand the scope of its platform and is entering the alternate medicine space (AYUSH categories) through the acquisition of www. Homeobuy.com. Homeobuy is a web platform for homeopathy medicines. With this acquisition, 1mg will re-brand the website to www. 1mgAyush.com and make Homeopathic & Ayurvedic medicines available to customers in New Delhi.

    [adsense:336x280:8701650588]

  • India and the European Union will soon begin research on health with focus on 'Diagnostics and interventions in chronic non-communicable diseases'.  Main aim behind this collaboration is to support high quality research and development of tools and technologies for the diagnostics of chronic non-communicable diseases; research and innovation within interventions for chronic non-communicable diseases; and mechanisms in chronic non-communicable diseases. This will strengthen scientific, technology and business collaborations between Europe and India.

  • Savitribai Phule Pune University’s department of Interdisciplinary School of Health Sciences and Institute of Bioinformatics and Biotechnology have proved that Triphala, a widely used ayurvedic formulations, effective  against a wide range of diseases like cardiovascular diseases, asthma, arthritis, diabetes and cancer. The team of scientists Uma Chandran, Neelay Mehendale, Girish Tillu and Prof. Bhushan Patwardhan used a technique known as poly-pharmacology. Triphala formulation as a whole contains 174 bioactives.

  • Sandoz, a Novartis company, has launched Glatopa in US markets. Glatopa is the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. It is used in treatment of Multiple Sclerosis (MS).

  • Intas Pharmaceuticals on Friday announced launching of Razumab, a biosimilar to Lucentis (ranibizumab). Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up.  Razumab will be 25 per cent cheaper than its imported alternate.

  • A study led by researchers at Case Western Reserve and UT Southwestern Medical Center  showed An experimental drug  help by regrow damaged liver, colon and bone marrow tissue in laboratory mice.  Now scientist trying to work in humans. However, experts cautioned that their research is at a very early stage, and more work is needed before it can be tested in humans. This experimental drug is now known only as SW033291. It can shut down the activity of a gene product found in all humans, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), that in turn allows room for more prostaglandin E2, which encourages many types of tissue stem cells to grow and promotes healing.

  • 24 June 2015
    Lilly, Dana-Farber Cancer Institute collaborate to develop new medicines to treat cancer

    Eli Lilly and Company and Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School,  collaborate  to research new medicines under development  to fight cancer.

  • An antidepressant and a heart drug approved for use in humans may also help treat the deadly Ebola disease, a new study in mice suggests. Researchers screened about 2,600 compounds for their ability to hinder Ebola's activity, and identified 30 drugs that were effective against the virus in a lab dish. Two of the drugs — the antidepressant sertraline and a heart drug called bepridil - appeared particularly promising for their action against Ebola. The drugs appear to inhibit Ebola infection by preventing the genetic material of the virus from getting inside the host's cells.

  • Daiichi Sankyo Company, Limited's generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients. The products: Naftopidil OD tablets 25mg, 50mg, 75mg “DSEP” (Flivas OD tablets 25mg, 50mg, 75mg) for the treatment for urination disorder due to enlargement of prostate; Metformin hydrochloride tablets 250mgMT, 500mgMT “DSEP” (Metgluco tablets 250mg, 500mg) for biguanide-type oral hypoglycemic agent; Letrozole tablets 2.5mg “DSEP” (Femara tablets 2.5mg)  Aromatase inhibitor/postmenopausal breast cancer treatment; Oxaliplatin IV infusion solution 200mg “DSEP” (Elplat IV infusion solution 200mg) anti-malignant tumour agent.

  • Cinnamaldehyde, chemical constituent of  cinnamon has distinctive flavor and smell. Associate Professor Georg Wondrak, and Professor Donna Zhang, at the University of Arizona recently completed a study in which they proved that adding cinnamaldehyde, the compound that gives cinnamon its distinctive flavor and smell, to the diet of mice protected the mice against colorectal cancer. In response to cinnamaldehyde, the mice's cells had acquired the ability to protect themselves against exposure to a carcinogen through detoxification and repair.

Subscribe to Pharma News